Biosight Reports Final Primary Endpoint Data from Phase 2b Study of Aspacytarabine (BST-236) for First-Line Acute Myeloid Leukemia Therapy
06 janv. 2022 16h05 HE
|
BioSight Ltd.
Complete remission rate of 37%, of which 50% were minimal residual disease negative Single-agent activity and favorable safety demonstrated in most challenging AML patient populations Study results...
Biosight Announces Initiation of Phase 2 Clinical Trial of Aspacytarabine for MDS and AML
12 nov. 2021 08h00 HE
|
BioSight Ltd.
U.S. Based Phase 2 Trial will Evaluate Aspacytarabine in Second Line Relapsed/Refractory MDS and AML across 18 Sites Builds Upon Ongoing Phase 2 Investigator Sponsored Study with the Groupe...
Biosight Encourages Advaxis Stockholders to Vote “FOR” Proposed Merger
11 nov. 2021 08h00 HE
|
BioSight Ltd.
Combined company, to be named Biosight Therapeutics, expected to be well-positioned to leverage its compelling oncology therapeutics pipeline, strong cash position, and accomplished management and...
Biosight Announces Upcoming Presentation at the 63rd American Society of Hematology Annual Meeting
04 nov. 2021 09h36 HE
|
BioSight Ltd.
AIRPORT CITY, Israel, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...
Biosight Announces Initiation of Investigator Sponsored Phase 2 Clinical Trial of Aspacytarabine for Relapsed/Refractory AML and MDS with the Groupe Francophone des Myélodysplasies
16 août 2021 08h00 HE
|
BioSight Ltd.
First Patient Enrolled to the Phase 2 Trial, which will Evaluate Single-Agent Aspacytarabine in Second Line Relapsed/Refractory AML and MDS Study sponsored by Groupe Francophone des Myélodysplasies,...
Biosight Presents Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) in an Oral Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
04 juin 2021 08h00 HE
|
BioSight Ltd.
Complete remission rate of 39%, of which 63% were minimal residual disease negative, achieved in expanded data set in frontline acute myeloid leukemia Durable responses with median overall survival...
Biosight Appoints Dr. Darrel Cohen as Chief Medical Officer
18 mai 2021 09h05 HE
|
BioSight Ltd.
Industry veteran brings successful track record of clinical development and marketing authorizations of several cancer and leukemia drug products Appointment establishes US presence of senior...
Biosight Completes Enrollment in Phase 2b Study of Aspacytarabine (BST-236) for First-Line Acute Myeloid Leukemia Therapy
11 mai 2021 08h30 HE
|
BioSight Ltd.
Encouraging data support single-agent efficacy across key measures including complete remission (CR) with negative minimal residual disease (MRD) rates, duration of response and overall survival in...
Biosight to Present Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2021 ASCO Annual Meeting
28 avr. 2021 16h31 HE
|
BioSight Ltd.
AIRPORT CITY, Israel, April 28, 2021 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders,...
Biosight Receives Orphan Medicinal Product Designation from the European Medicines Agency for Aspacytarabine (BST-236) for the Treatment of Acute Myeloid Leukemia
17 déc. 2020 08h00 HE
|
BioSight Ltd.
AIRPORT CITY, Israel, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...